Harglim M 1 Forte Tablet SR is a combination oral antidiabetic medication containing Glimepiride 1 mg and Metformin 1000 mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to better glycemic control. The sustained-release formulation of Harglim M 1 Forte ensures a gradual release of metformin, optimizing plasma concentrations and minimizing gastrointestinal side effects commonly associated with immediate-release formulations. This combination therapy is indicated for patients inadequately controlled on diet and exercise alone or those requiring additional glycemic control beyond monotherapy. It is essential to monitor blood glucose levels regularly and adjust dosages based on therapeutic response and tolerability. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or conditions predisposing to hypoglycemia. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and, rarely, lactic acidosis. Harglim M 1 Forte should be used under medical supervision with lifestyle modifications to achieve optimal diabetes management and reduce the risk of long-term complications.

Dosage & How to Use